Amylyx Pharmaceuticals, Inc.
AMLX · Nasdaq · United States
Share price · AMLX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AMLX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 16 Nov 2026-8.2%
Nothing announced by AMLX that day or the session before.
- 18 Aug 2026+63.8%
- 7 Aug 2026-5.7%
- 6 Aug 2026+10.7%
- 4 Aug 2026+8.4%
Nothing announced by AMLX that day or the session before.
- 27 Jul 2026+5.9%
Nothing announced by AMLX that day or the session before.
- 24 Jul 2026+4.7%
Nothing announced by AMLX that day or the session before.
- 14 Jul 2026+4.5%
Nothing announced by AMLX that day or the session before.
- 4 Jun 2026+8.4%
- 20 Jan 2026+15.7%
Nothing announced by AMLX that day or the session before.
Share of unusual movement by asset
For each asset, the share of AMLX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
avexitideevents and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 30% |
| Other company news (earnings, financing, releases naming no asset) | — | 15% |
| Sessions with no dated event | — | 55% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptor (antagonist)Peptide | Hyperinsulinemic Hypoglycemia Post-Bariatric Hypoglycemia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $28M | $240M+ $528M short-term inv. | $45M-$34M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $24M | $49M+ $201M short-term inv. | $43M-$31M operating cash flow | report ↗ |
| 2026-Q1 | — | $28M | $229M+ $51M short-term inv. | $41M-$37M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $20M | $225M+ $119M short-term inv. | $34M-$30M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $27M | $58M+ $123M short-term inv. | $41M-$25M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $22M | $60M+ $144M short-term inv. | $36M-$40M operating cash flow | report ↗ |
| 2024-Q3 | $0.4M | $21M | $72M+ $163M short-term inv. | $73M-$42M operating cash flow | report ↗ |
| 2024-Q2 | -$1.0M | $23M | $75M+ $235M short-term inv. | $73M-$67M operating cash flow | report ↗ |
| 2024-Q1 | $89M | $37M | $171M+ $203M short-term inv. | $119M-$0.5M operating cash flow | report ↗ |
| 2023-Q3 | $103M | $30M | $135M+ $220M short-term inv. | —-$5.2M operating cash flow | report ↗ |
| 2023-Q2 | $98M | $29M | $248M+ $110M short-term inv. | —$8.6M operating cash flow | report ↗ |
| 2023-Q1 | $71M | $24M | $115M+ $231M short-term inv. | —-$5.1M operating cash flow | report ↗ |
| 2022-Q3 | $0.3M | $25M | $108M+ $55M short-term inv. | $54M-$43M operating cash flow | report ↗ |
| 2022-Q2 | — | $24M | $67M+ $139M short-term inv. | $54M-$46M operating cash flow | report ↗ |
| 2022-Q1 | — | $21M | $110M+ $145M short-term inv. | $48M-$41M operating cash flow | report ↗ |
| 2021-Q3 | — | $13M | — | $23M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $90M | $227M+ $90M short-term inv. | $36M-$123M operating cash flow | report ↗ |
Amylyx Pharmaceuticals reported full-year 2025 revenue of $0M, down 100.0% YoY, with R&D spend of $90.4M, down 13.1% YoY. The company held cash and equivalents of $226.65M and posted a net loss of $144.74M.
Management guided to a cash runway into 2028. Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia is complete, with topline data expected in Q3 2026 and potential commercialization in 2027 if approved. The company also presented early safety data from Cohort 1 of the Phase 1 LUMINA trial of AMX0114 in ALS, expects Cohort 2 enrollment completion in March 2026, and selected AMX0318 as a development candidate with an IND filing targeted for 2027.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $87M | $104M | $77M+ $99M short-term inv. | $75M-$168M operating cash flow | report ↗ |
| 2023-FY | $381M | $128M | $170M+ $201M short-term inv. | —$12M operating cash flow | report ↗ |
| 2022-FY | $22M | $93M | $63M+ $284M short-term inv. | $50M-$180M operating cash flow | report ↗ |
| 2021-FY | — | $44M | $50M+ $46M short-term inv. | $22M-$75M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($152K), 39 sales ($17.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-10 | FRATES JAMES M · Chief Financial Officer | Option exercise | 20,000 | $6.88 | $138K | Form 4 |
| 2026-11-10 | FRATES JAMES M · Chief Financial Officer | Open-market sale | 12,800 | $30.32 | $388K | Form 4 |
| 2026-11-10 | FRATES JAMES M · Chief Financial Officer | Open-market sale | 7,200 | $30.97 | $223K | Form 4 |
| 2026-11-10 | FRATES JAMES M · Chief Financial Officer | Option exercise (derivative) | 20,000 | — | — | Form 4 |
| 2026-11-09 | Cohen Joshua B · director, Co-Chief Executive Officer | Open-market sale | 38,105 | $29.39 | $1.1M | Form 4 |
| 2026-11-09 | Klee Justin B. · director, Co-Chief Executive Officer | Open-market sale | 37,483 | $29.39 | $1.1M | Form 4 |
| 2026-11-09 | FRATES JAMES M · Chief Financial Officer | Option exercise | 20,000 | $6.88 | $138K | Form 4 |
| 2026-11-09 | Cohen Joshua B · director, Co-Chief Executive Officer | Open-market sale | 61,895 | $30.11 | $1.9M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 171 reporting institutions held 114.8M shares ($1.6B, 89.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 16,630,541 | $231.2M |
| 2 | BlackRock, Inc. | 8,828,836 | $122.7M |
| 3 | PERCEPTIVE ADVISORS LLC | 8,284,882 | $115.2M |
| 4 | TCG Crossover Management, LLC | 6,243,812 | $86.8M |
| 5 | Commodore Capital LP | 5,650,000 | $78.5M |
| 6 | JANUS HENDERSON GROUP PLC | 4,986,073 | $69.3M |
| 7 | Saturn V Capital Management LP | 4,349,885 | $60.5M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 4,141,575 | $57.6M |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,560,764 | $49.5M |
| 10 | First Light Asset Management, LLC | 3,190,645 | $44.3M |
| 11 | Driehaus Capital Management LLC | 2,987,147 | $41.5M |
| 12 | GOLDMAN SACHS GROUP INC | 2,625,991 | $36.5M |
| 13 | STATE STREET CORP | 2,363,161 | $32.8M |
| 14 | FRANKLIN RESOURCES INC | 2,261,569 | $31.4M |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 2,210,932 | $30.7M |